ABCL Rasio cepet AbCellera Biologics Inc

AbCellera Biologics (ABCL) specializes in AI-powered accelerated antibody discovery. The share price history on GURU.Markets confirms the company's significant pricing power driven by royalties and inelastic demand, with the current metric standing at 12.49. The capacity of its research centers and computing clusters continues to grow without base depreciation. However, cash inflows remain volatile as they depend on partner payments.

AbCellera Biologics (ABCL) ability to withstand external shocks depends on the ratio of cash and accounts receivable to short-term debt, excluding inventory. Scaling autonomous microfluidic systems requires significant expenditure; therefore, this quick liquidity chart allows investors to assess the company's actual margin of safety and its capacity to immediately settle obligations without relying on the sale of illiquid assets.